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The GLP‑1 receptor agonist, 
liraglutide, fails to slow disease 
progression in  SOD1G93A 
and TDP‑43Q331K transgenic mouse 
models of ALS
Amy Keerie1, Heledd Brown‑Wright1, Isaac Kirkland1, Andrew Grierson1, James J. P. Alix1, 
Christian Holscher2,3 & Richard J. Mead1*
GLP‑1 receptor agonists used for the treatment of diabetes, have shown some neuroprotective 
effects in cellular and animal models of Alzheimer’s disease (AD) and Parkinson’s disease (PD). There 
are currently few studies investigating GLP‑1 receptor agonists in the treatment of ALS, where these 
neuroprotective effects may be beneficial. Here we investigate the effects of liraglutide, a GLP‑1 
receptor agonist, in two well characterised transgenic mouse models of ALS  (SOD1G93A and TDP‑
43Q331K) to determine if liraglutide could be a potential treatment in ALS patients. Doses of liraglutide 
previously shown to have efficacy in AD and PD mouse models were used. Behavioural testing was 
carried out to ascertain the effect of liraglutide on disease progression. Immunohistochemical analysis 
of tissue was used to determine any neuroprotective effects on the CNS. We found that liraglutide 
dosed animals showed no significant differences in disease progression when compared to vehicle 
dosed animals in either the  SOD1G93A or TDP‑43Q331K mouse models of ALS. We also observed no 
changes in motor neuron counts or glial activation in lumbar spinal cords of liraglutide treated mice 
compared to vehicle dosed mice. Overall, we found no evidence to support clinical evaluation of 
liraglutide as a potential candidate for the treatment of ALS.
There is increasing evidence that Glucagon Like Peptide 1 (GLP-1) Receptor agonists have therapeutic potential 
in neurodegenerative diseases. These agents were developed for the treatment of diabetes mellitus but several 
trials are underway in both Parkinson’s disease (PD) and Alzheimer’s disease (AD). These trials were stimulated 
by extensive preclinical data showing that these agents have neuroprotective and anti-inflammatory  properties1. 
However, such data is not available for motor neuron disease. We set out to evaluate this clinically approved, 
CNS penetrating therapeutic in two mouse models of Amyotrophic lateral sclerosis (ALS). If positive, this data 
could directly support a clinical trial with liraglutide in ALS.
The concept of exploring the therapeutic utility of anti-diabetic agents in both AD and PD came from multiple 
independent studies showing that diabetes is a risk factor for these  diseases2,3. Further evidence at the histological 
and biochemical level using patient derived material indicated that insulin insensitivity was a general feature 
of these diseases in the majority of patients, regardless of diabetic  status4–6. Early studies of insulin resistance 
in ALS indicated an association of disease with diabetes and later studies found a strong association with type 
I diabetes but not type II diabetes, indeed some studies have indicated a protective effect of Type II  diabetes7.
As well as established functions in glucose homeostasis, insulin acts as a growth factor and the receptor is 
expressed in neurons where it can mediate neurotrophic effects and neuroprotection from stressors including 
oxidative  stress8. In terms of therapeutic utility, insulin is problematic as chronic administration in non-diabetics 
has significant risk. An alternative are anti-diabetic agents such as the GLP-1 mimetics which have been devel-
oped to normalise insulin signalling in diabetic patients with great success. Crucially, these molecules have a 
good safety profile within non-diabetic  patients3.
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It is worth noting that a trial of the anti-diabetic agent pioglitazone (PPARγ agonist) in ALS with the rationale 
of attenuating inflammation, failed to show any  benefit9. Importantly this was based on two preclinical efficacy 
studies in the  SOD1G93A mouse which did not account for the now well described pitfalls in experimental  design10, 
which have led to new guidelines for preclinical research. In addition, many investigators also advocate testing 
in additional genetic models, and not just those based on mutant SOD1  overexpression11. The use of different 
model systems increases the confidence in translation from mouse to human studies.
Previous investigations with liraglutide in multiple preclinical AD and PD models have demonstrated neu-
roprotection. Importantly GLP-1 is brain  penetrant12, as is  liraglutide13, which is currently marketed for use in 
diabetic patients. The GLP-1 receptor is expressed in the CNS in neurons and reactive glia and the effects of 
liraglutide include inhibition of inflammation and improvement in synaptic connectivity in multiple in vivo 
models of AD and  PD1. The predominant effective dose used in mouse studies is 25 nmol/kg. This dose was also 
shown to reduce the symptoms of Alzheimer’s disease in the APP/PS1 transgenic mouse  model14–16. Liraglutide 
treatment in a different mouse model of AD also provided metabolic improvements in the triple transgenic mouse 
model of AD using 18F deoxy glucose-PET  studies17. These observations are also in keeping with those observed 
in a recent human clinical trial in AD at the clinically approved  doses18 and provide an excellent biomarker to 
match mouse doses to human intervention studies. Liraglutide at this dose furthermore reduced the pathology 
in the MPTP mouse model of Parkinson’s  disease19.
Studies in ALS models have also indicated potential beneficial effects of GLP-1 receptor agonism. In vitro 
studies showed neuroprotective effects of the GLP-1 analog, N-acetyl-GLP-1 (7-34) amide against excitotoxic 
damage in purified embryonic motor neurons derived from  SOD1G93A transgenic  mice20. In vivo studies have 
shown a protective effect when mesenchymal stromal cells engineered to produce GLP-1 were transplanted 
directly into brain  ventricles21 and the GLP-1 analog  exenatide22 in an ALS mouse model, however there are still 
limited studies investigating this in ALS.
In order to gain a better understanding of the role of GLP-1 agonists in ALS and their potential for clinical 
translation we conducted in vivo pharmacology studies with liraglutide following established guidelines for pre-
clinical  testing11. We used two strains of transgenic mice which replicate features of ALS, an optimised  SOD1G93A 
transgenic  model23 and a TDP-43Q331K transgenic  line24.
Results
Liraglutide does not alter behavioural markers of ALS in a TDP‑43Q331K model of ALS. TDP-
43Q331K transgenic female mice were dosed IP daily with vehicle or 25 nmol/kg liraglutide from 25 to 180 days 
of age. Animals were weighed daily over the duration of dosing. The TDP-43Q331K transgenic mice weigh more 
than their wild type litter mates and gradually gain  weight25. All mice in this study put on weight gradually 
from 25 days of age until the end of the study however, there was no significant difference between the two dose 
groups. At 30 days of age vehicle and liraglutide animals weighed 13.6 ± 1.4 g and 14.0 ± 0.9 g respectively, and 
at 6 months vehicle animals weighed 27.9 ± 3.2 g and liraglutide dosed animals weighed 27.0 ± 2.8 g (Fig. 1A) 
(overall P value = 0.7442, two-way ANOVA with repeated measures).
Animals were tested on the rotarod once a week from 6 weeks of age. The TDP-43Q331K transgenic mice dosed 
with vehicle showed a gradual decline in rotarod performance over the duration of dosing as expected, however 
there was no significant difference between liraglutide dosed animals and vehicle dosed animals. Vehicle dosed 
animals on average fell after 291.9 ± 15.1 s at 6 weeks of age and 195.4 ± 71.8 s at 6 months of age and liraglutide 
dosed animals fell on average after 289.2 ± 16.1 s at 6 weeks of age and 198.1 ± 63.0 s at 6 months of age (Fig. 1B) 
(overall P value = 0.5741, two-way ANOVA with repeated measures).
Compound muscle action potential (CMAP) is a representation of functional motor axons and muscle fibres. 
Thus, CMAP amplitude is dependent upon the number of axons, fidelity of neuromuscular transmission, and 
number/size of muscle fibres. TDP-43Q331K transgenic mice have a lower CMAP than their wild type litter mates at 
3 and 6 months of  age25. The average CMAP for vehicle dosed mice was 29.4 ± 7.0, 29.5 ± 4.0 and 29.5 ± 4.5 at the 
6-week, 3-month and 6-month timepoints respectively versus 31.6 ± 5.6, 30.2 ± 3.7 and 28.5 ± 4.0 for liraglutide 
dosed mice. There was no significant difference between liraglutide and vehicle dose groups at any time point 
(Fig. 1C) (overall P value = 0.5655, two-way ANOVA with repeated measures).
Quantitative gait analysis was carried out at 3 and 6 months of age using the Catwalk gait analysis system 
(Noldus). Hindlimb base of support (BOS) is the distance between the two hind paws during the step cycle. 
There is an increase in hindlimb BOS from 3 to 6 months in both groups in the study with no significant dif-
ference between the two groups at either time point. Vehicle dosed mice had an average BOS of 25.5 ± 2.3 mm 
and 30.0 ± 0.6 mm at 3 months and 6 months respectively verses 26.2 ± 3.2 mm and 29.0 ± 2.3 mm for liraglutide 
dosed animals (Fig. 1D) (overall P value = 0.8974, two-way ANOVA with repeated measures). This increase in 
BOS over time could be due to the increase in weight of these mice or reduced motor coordination.
The general walking pattern of wild-type mice shows a high percentage of time in diagonal walking where 
opposite forepaw and hindpaw are in contact with the ground at the same time, a higher percentage of time on 
3 or 4 paws shows instability. The percentage of time spent on diagonal paws decreases between 3 and 6 months 
for both vehicle and liraglutide dosed animals but there was no significant difference between the groups. Vehicle 
dosed mice had an average percentage of time spent on diagonal paws of 60.8 ± 8.6% and 57.8 ± 8.9% at 3 months 
and 6 months respectively verses 63.8 ± 8.3% and 60.0 ± 9.3% for liraglutide dosed animals (Fig. 1E) (overall P 
value = 0.5215, two-way ANOVA with repeated measures). As well as the decrease in diagonal walking there 
was an increase in the time spent on four paws, however, there is no significant difference between the two 
groups. Vehicle dosed mice had an average percentage of time spent on four paws of 10.9 ± 4.0% and 13.0 ± 4.3% 
at 3 months and 6 months respectively verses 7.6 ± 4.7% and 12.1 ± 3.1% for liraglutide dosed animals (Fig. 1F) 
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Figure 1.  Liraglutide, dosed once daily at 25 nmol/kg IP does not slow disease progression in a TDP-43Q331K 
transgenic mouse model of ALS. (A) Daily average body weight (mean ± SD) of mice dosed with vehicle or 
liraglutide, once daily, ip from 25 days to 6 months of age. As expected, TDP-43Q331K mice gain weight through 
to 6 months of age. No significant difference was seen in bodyweight data between the two groups (n = 14 per 
group, two-way ANOVA with repeated measures P = 0.7442). Average shown by thick line, ± SD shown by 
thin dashed lines (B) Rotarod data shown as average latency to fall (mean ± SD) from 50 to 180 days of age. 
Performance on rotarod declined over time as expected from the model but there was no significant difference 
between the two dose groups (n = 14 per group, two-way ANOVA with repeated measures P = 0.5741). (C) 
Compound muscle action potential (CMAP) amplitude at 6 weeks, 3 months and 6 months of age shown as 
individual values with mean ± SD. There is no significant difference in CMAP between groups (n = 14 per group, 
two-way ANOVA with repeated measures P = 0.5655). (D) Hindlimb base of support (mean ± SD) at 3 and 
6 months of age from gait analysis shows no significant difference between dose groups (n = 7 per group, two-
way ANOVA P = 0.8974 NS). (E) Percentage of time spent on diagonal walking (mean ± SD) at 3 and 6 months 
of age (n = 7 per group, two-way ANOVA P = 0.5215 NS). (F) Percentage of time spent on four paws (mean ± SD) 
at 3 and 6 months of age (n = 7 per group, two-way ANOVA P = 0.3100 NS).
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(overall P value = 0.3100, two-way ANOVA with repeated measures). This decrease in diagonal and increase in 
4 paw walking indicates instability and loss of motor coordination as the mice age.
Overall, there was no change in behavioural data between liraglutide dosed and vehicle dosed animals in 
TDP-43Q331K transgenic mice at a dose level of liraglutide that has shown previous beneficial effects in Alzheimer’s 
disease and Parkinson’s  disease15,19. In order to investigate higher dose levels and gain a broader understanding 
of the potential of liraglutide, a further set of experiments was conducted in  SOD1G93A transgenic mice.
Liraglutide lowers blood glucose levels in  SOD1G93A transgenic mice. Following on from the 
TDP-43Q331K mouse study a target engagement study was carried out in  SOD1G93A transgenic mice. This was 
to determine if the dose of liraglutide was affecting glucose levels at the previously used 25 nmol/kg liraglutide 
dose and a higher dose of 75 nmol/kg liraglutide. Mice were dosed with vehicle, 25 and 75 nmol/kg liraglutide 
IP and a small amount of blood was collected from the tail at multiple time points to determine blood glucose 
levels. Baseline glucose levels increased at 15 min post dose for all groups, probably due to stress of handling and 
dosing. Over the next 24 h the glucose levels decreased in all of the dose groups in a dose dependant manner 
with the vehicle group having the slowest decline in glucose level over time. There was a significant decrease in 
blood glucose levels of the 75 nmol/kg liraglutide dosed group when compared to the vehicle dosed group at 60 
(P = 0.0285) and 120 (P = 0.0236) minutes post dose (Fig. 2) (two-way ANOVA with repeated measures).
Liraglutide does not alter behavioural markers of ALS in  SOD1G93A transgenic mice. Due to the 
tolerated higher 75 nmol/kg liraglutide dose and the larger effect on blood glucose levels, we dosed  SOD1G93A 
transgenic mice with vehicle, 25 nmol/kg or 75 nmol/kg liraglutide from 25 to 90 days of age. From 25 to 45 days 
of age mice rapidly put on weight, which then plateaued for the duration of the study (Fig. 3A). There was no 
overall difference between the liraglutide dosed animals and vehicle dosed animals in terms of weight. At 88 days 
of age vehicle, 25 nmol/kg and 75 nmol/kg dosed animals weighted 17.1 ± 0.9 g, 17.8 ± 1.1 g and 17.6 ± 1.2 g 
respectively (overall P = 0.3165, two-way ANOVA with repeated measures).
Rotarod testing was carried out twice a week from 6 weeks of age. There was a steady decline in rotarod 
performance from the 6-week time point, as expected in the model; however, there was no significant differ-
ence between the different groups when compared to vehicle dosed animals. The average time to fall for vehicle 
dosed mice was 284.8 ± 47.6 s and 212.9 ± 80.6 s at 5 weeks and 12 weeks respectively, verses 286.4 ± 25.9 s and 
187.1 ± 62.9 s for 25 nmol/kg liraglutide dosed mice, and 270 ± 45.7 s and 167.5 ± 55.3 s for 75 nmol/kg liraglutide 
dosed mice (Fig. 3B, overall P = 0.5252, two-way ANOVA with repeated measures).
Onset of visible signs was determined from the combined onset of hind limb splay defects and tremor. There 
was no significant difference in age of disease onset between the liraglutide dosed animals and vehicle dosed 
animals. Average age of visible signs of onset for vehicle, 25 nmol/kg liraglutide dose animals and 75 nmol/kg 
liraglutide dosed animals was 68.9 ± 2.7 days, 69.2 ± 2.9 days and 70.1 ± 5.1 days respectively (Fig. 3C, overall 
P = 0.7026, one-way ANOVA with Sidak’s multiple comparison).
Quantitative gait analysis was carried out at 70 and 84 days of age. No significant difference was observed 
between liraglutide dosed and vehicle dosed mice in hindlimb stride length (P = 0.1298, Fig. 3D), percentage of 
time spent on diagonal paws (P = 0.7074, Fig. 3E) or percentage of time spend on three paws (P = 0.9653, Fig. 3F) 
(two-way ANOVA with repeated measures).
Liraglutide shows no effect on motor neuron count, or glial responses in the lumbar spinal 
cord of  SOD1G93A transgenic mice. Since there was no effect of liraglutide on behavioural parameters 
we examined pathology in lumbar spinal cord from the end of the study when the  SOD1G93A transgenic mice 
were 90 days old. We first looked at astrocyte and microglia staining of lumbar spinal cord sections using GFAP 
and Iba1 antibodies respectively (Fig. 4A). There was no significant difference in GFAP percentage area stained 
with 9.2 ± 1.6%, 8.8 ± 2.2% and 8.8 ± 2.0% area coverage for vehicle dosed, 25 nmol/kg and 75 nmol/kg liraglutide 
dosed respectively (P = 0.7824, one-way ANOVA) (Fig. 4B). There was also no significant difference in integrated 
Figure 2.  75 nmol/kg liraglutide reduces blood glucose levels in  SOD1G93A mice. Blood glucose levels measured 
on an optium geo glucose meter at multiple time points post dose with vehicle, 25 and 75 nmol/kg liraglutide 
(mean ± SD). There is a significant decrease in glucose levels at 60 (P = 0.0285) and 120 (P = 0.0236) minutes post 
dose in the 75 nmol/kg liraglutide group compared to vehicle (n = 4 per group, two-way ANOVA).
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density of GFAP staining between vehicle and 25 nmol/kg or 75 nmol/kg liraglutide with values of 9047 ± 2425, 
10,258 ± 2630 and 8866 ± 2949 respectively (P = 0.9754, one-way ANOVA) (Fig. 4C).
There was also no significant difference in area stained for Iba1 with 7.0 ± 1.7%, 6.8 ± 1.3% and 7.1 ± 1.1% 
area coverage for vehicle, 25 nmol/kg and 75 nmol/kg liraglutide dosed animals (P = 0.7107, one-way ANOVA) 
(Fig. 4D). Nor was there a difference in circularity of Iba1 staining with values of 0.32 ± 0.01, 0.32 ± 0.01 and 
0.32 ± 0.02 for vehicle, 25 nmol/kg and 75 nmol/kg liraglutide respectively (P = 0.9927, one-way ANOVA) 
(Fig. 4E).
Motor neurons counts from lumbar spinal cord sections stained with Nissl at 90 days of age showed no 
significant difference in the average number of motor neurons per ventral horn between the two liraglutide 
dosed groups and the vehicle dosed group. The vehicle, 25 nmol/kg, and 75 nmol/kg dosed mice had an average 
of 15.7 ± 2.1, 15.4 ± 3.2 and 15.8 ± 2.4 motor neurons per section respectively (P = 0.9582, one-way ANOVA) 
(Fig. 4F).
Discussion
We investigated the effect of liraglutide, a GLP-1 receptor agonist, in two mouse models which recapitulate some 
features of ALS pathophysiology and found no evidence that disease progression was altered at the behavioural 
or pathological level.
The  SOD1G93A mouse model is the most commonly used mouse model to test potential therapeutics for ALS 
however, it has poor translation to human  studies26 and may only represent patients with SOD1 mutations. The 
TDP-43Q331K mouse model used in this study may be more representative of ALS patients and also shows signs of 
having an FTD-like phenotype with remarkable similarities to a more physiological knock-in  model25. However, 
Figure 3.  Liraglutide dosed once daily at 25 or 75 nmol/kg does not alter progression of disease in a  SOD1G93A 
mouse model of ALS. (A) Daily average body weight (mean ± SD) from 25 to 90 days of age of mice dosed with 
vehicle, 25 or 75 nmol/kg liraglutide once daily ip. Average shown as thick line and SD shown as thin dashed 
lines. No significant difference in body weight between liraglutide dosed and vehicle dosed animals (n = 14 
per group, two-way ANOVA, P = 0.3165). (B) Rotarod data shown as latency to fall (mean ± SD) from 40 to 
90 days of age. As expected, rotarod performance declined over time but there was no significant difference 
between vehicle and liraglutide dosed mice (n = 14 per group, two-way ANOVA, P = 0.5252). (C) Age of visible 
onset measured through twice weekly motor scoring shown as individual values with mean ± SD (n = 14 
per group, one-way ANOVA, P = 0.7026). (D) Hindlimb stride length (mean ± SD) at 70 and 84 days of age 
showed no difference between liraglutide dosed and vehicle dosed animals (n = 8 per group, two-way ANOVA, 
P = 0.1298). (E) Percentage of time spent on diagonal paws (mean ± SD) at 70 and 84 days of age showed no 
difference between vehicle dosed and liraglutide dosed mice (n = 8 per group, two-way ANOVA, P = 0.7074). (F) 
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this model does not have the TDP-43 proteinopathy found in the majority of ALS  patients24. The use of two 
different mouse models and adherence to the published preclinical guidelines for  ALS11 gives more confidence 
in the lack of effect for liraglutide.
GLP-1 receptor agonists increase insulin levels and therefore lower blood glucose levels and insulin plays 
an important role in CNS mediated regulation of glucose and energy homeostasis as well as on memory, and 
 mood27. However, liraglutide may also have an effect on several other pathways linked to  neuroprotection28. 
Although GLP-1 receptor agonists have shown a range of neuroprotective properties, there is a clearer link 
between insulin pathway deficiencies in AD and PD compared to ALS. For example, obesity is a risk factor for 
AD and disruption of insulin signalling in the brain leads to a higher risk of  AD29, however ALS patients tend to 
be hypermetabolic and it has been shown that increasing glucose levels in models of ALS is  protective30. There 
is less evidence connecting insulin signalling and risk of ALS as there is with AD and PD.
A previous study looked at a different GLP-1 receptor agonist, exendin-4, in a  SOD1G93A mouse model and 
found no change in disease progression as measured by rotarod performance and a decrease in running wheel 
but a greater than threefold increase in motor neuron count both pre-onset and at end-stage22. These results are 
Figure 4.  GFAP, Iba1 and Nissl staining of  SOD1G93A lumbar spinal cord shows no difference between 
liraglutide and vehicle dosed animals in a  SOD1G93A mouse model. All fluorescence images were captured on the 
INCELL 2000 (GE) at 60 × magnification. (A) Representative images of DAPI, Iba1 and GFAP staining of ventral 
horns from lumbar spinal cord sections from vehicle, 25 nmol/kg and 75 nmol/kg liraglutide dosed  SOD1G93A 
mice at 90 days of age. Scale bar is 50 μm. (B) Quantification of percentage area coverage of GFAP staining 
plotted as individual values with mean ± SD shows no significant difference between vehicle and liraglutide 
dosed mice (n = 7 or 8 per group, one-way ANOVA, P = 0.7824). (C) Integrated density of GFAP staining 
plotted as individual values with mean ± SD shows no significant difference between liraglutide and vehicle 
dosed groups (n = 7 or 8 per group, one-way ANOVA, P = 0.9754). (D) Iba1 percentage area coverage plotted 
as mean ± SD shows no significant difference between liraglutide and vehicle dosed mice (n = 7 or 8 per group, 
one-way ANOVA, P = 0.7107) (E) Circularity of Iba1 staining shown as individual values with mean ± SD shows 
no significant difference between liraglutide and vehicle dosed animals (n = 7 or 9 per group, one-way ANOVA, 
P = 0.9927). (F) Motor neuron counts from Nissl stained lumbar spinal cord sections shown as individual values 
with mean ± SD shows no significant difference between liraglutide and vehicle dosed animals (n = 7 or 8 per 
group, one-way ANOVA, P = 0.9582).
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difficult to reconcile since the motor phenotype in  SOD1G93A mice is clearly linked to motor neuron degeneration 
and loss. We saw no change in disease progression and no such preservation of motor neurons upon liraglutide 
treatment. Both the Li et al. study and the present study investigated astrocyte reactivity by GFAP staining, and 
we did not observe the decrease of GFAP staining seen in the Li et al. study. A second study investigated delivery 
of GLP-1 in a  SOD1G93A mouse model using an intracerebroventricular injection of mesenchymal stem cells 
(MSC) stably transfected to secrete GLP-121. A significant improvement in weight, survival and rotarod perfor-
mance was seen in the MSC/GLP-1 treated animals compared to vehicle treated animals. Although this suggests 
neuroprotective effects of GLP-1, it is not possible in this study to separate protective effects of the mesenchymal 
stem cells themselves, from the effect of liraglutide, since a non-GLP transfected MSC control was not used. 
Indeed, we and others have shown direct protective effects of mesenchymal (bone marrow or adipose derived) 
stem cells in mutant SOD1 transgenic mouse models of  ALS31,32.
We cannot exclude the possibility that liraglutide may show beneficial effects on, for example, synaptic con-
nectivity, as described in other  models33,34. However, the data presented here in conjunction with clinical data 
on this mechanism in ALS suggests that it may not be of value to perform clinical studies with GLP-1 agonists 
in ALS and that resources may be more usefully focussed elsewhere.
Materials and methods
Ethics statement. All animal studies were carried out in accordance of the UK Animals (Scientific Proce-
dures) Act 1986 under a UK Home Office project license. This license was ethically reviewed and approved by 
the local ethics committee (University of Sheffield Animal Welfare and Ethical Review Body). Mouse mainte-
nance and day to day care was in line with the Home Office Code of Practice for Housing and Care of Animals 
Used in Scientific Procedures. The ARRIVE  guidelines35 were followed in the preparation of this paper.
Transgenic mice. The  SOD1G93A C57BL/6 transgenic mice were as described in a previous  paper23. In brief 
B6SJL-Tg(SOD1-G93A)1Gur/J mice were backcrossed for at least 20 generations onto the C57BL/6 J OlaHsD 
background.
TDP-43Q331K C57BL/6 N transgenic mice were obtained from the Jackson Laboratory, stock number 01793 
and were originally generated in the Cleveland  lab24 and extensively characterised in-house25.
Mice were housed in groups of between 2 and 5 with ad libitum access to food (standard rodent diet 2018, 
Evigo) and water. The temperature was maintained at 21 °C with a 12-h light/dark cycle. One plastic house was 
provided per cage, sawdust (Datesand) was used to cover the floor of the cages and paper wool (Datesand) was 
provided for nesting material.
Genotyping. Mice were ear clipped for identification and genotyping. DNA was extracted from earclips 
using 20 μl of Quickextract (Lucigen) and incubating at 65 °C for 15 min followed by 2 min at 98 °C.
Genotyping of TDP-43Q331K transgenic mice was carried out as described by Jackson  Laboratory36. Genotyp-
ing of  SOD1G93A transgenic mice was carried out as previously  described23.
Study design. For all the studies female transgenic mice were block randomised into the different dose 
groups. Power analysis (G Power version 3.0.3) was carried out on both models in order to determine the num-
ber of mice required to see a 20% improvement in rotarod performance. For the TDP-43Q331K and  SOD1G93A 
transgenic mouse studies 14 mice were used per dose group.
At the end of the study mice were euthanised with 2.5 ml/kg pentobarbitone. Under deep anaesthesia half of 
the animals were then perfused with ~ 5 ml PBS followed by 4% PFA, brain and spinal cord were collected for 
IHC analysis. The other half were euthanised with 2.5 ml/kg pentobarbitone followed by collection of blood, 
brain and spinal cord that were snap frozen.
Glucose measurements. Mice were not fasted before the start of the glucose experiment and had access to 
food ad libitum. A small amount of blood (6 μl) was collected directly onto a test strip from the tail of mice and 
analysed using an Optium Neo glucose testing kit (FreeStyle).
Liraglutide and dosing IP. Liraglutide was dissolved in sterile PBS at 0.037 mg/ml, aliquoted and frozen 
at -20 °C. On the day of dosing an aliquot was defrosted and diluted in PBS to 2.5 and 7.5 nmol/ml. Mice were 
dosed via intraperitoneal injection at 10 ml/kg. No adverse reactions were detected when dosing at 25 nmol/kg 
or 75 nmol/kg.
Rotarod. Rotarod testing was carried out using the protocol described  previously23. TDP-43Q331K transgenic 
mice were tested once a week and  SOD1G93A transgenic mice were tested twice a week from 6 weeks of age.
Catwalk gait analysis. Gait was captured using the catwalk gait analysis system 7.1 (Noldus). Mice vol-
untarily ran across a glass platform, and a camera mounted below captured the footsteps. Up to six runs were 
recorded for each mouse at each timepoint and the three straightest, most consistent runs are selected for analy-
sis. Image analysis of the gait pattern was carried out using the Catwalk analysis software (Noldus). The gait 
parameters analysed for each model correlated with those previously identified as being informative for tracking 
with disease  progression23,25.
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Neurological deficit scoring. SOD1G93A animals were scored three times a week for neurological deficit 
from 60 days of age as previously  described23. Onset of visible signs of disease is defined as a splay defect com-
bined with an abnormal gait score for two consecutive scoring days.
Electrophysiology. Electrophysiology was carried out at 6 weeks, 3 months and 6 months of age in the 
TDP-43Q331K transgenic mice. Mice were anesthetised using 5% gaseous isoflurane and 4 L/min oxygen flow 
rate. Once anesthetised animals were moved to a nose cone maintained at a 2% gaseous isoflurane and 0.5 L/
min oxygen flow rate. The left hind limbs were shaved and hair removal cream was used in order to remove all 
the fine fur. Ring electrodes were placed around the hind limb using Ten20 nerve conductive paste to ensure 
good contact with the skin. A ground electrode (Ambu Neuroline) was placed in the base of the tail and a pair 
of stimulating electrodes (Ambu Neuroline) were placed on the skin above the sciatic nerve at the level of the 
sciatic notch. Recordings were made using a Dantec Keypoint Focus EMG system. A square pulse of 0.1 ms dura-
tion was used and the current gradually increased to ensure a supramaximal compound muscle action potential 
(CMAP) response. The amplitude of the compound muscle action potential (CMAP) was used and is a measure-
ment of the output of all the stimulated axons and their target muscle.
Preparation of lumbar spinal cord sections. Mice were perfused with 4% PFA in PBS, spinal cord dis-
sected and post-fixed for 24 h. PFA fixed lumbar spinal cords (L3-L4) were cut in half and embedded in paraffin. 
Sections were cut at 10 μm thickness and placed onto glass slides. Immunohistochemistry (IHC) was carried out 
on 8 serial sections, 50 μm apart while Nissl staining was performed on a total of 16 serial sections, 50 μm apart. 
Sections were de-parrafinised and rehydrated by washing slides for 5 min in the following: 2 × 100% xylene, 
100% ethanol, 95% ethanol, 70% ethanol and  H2O.
Nissl staining. Rehydrated sections were incubated in a 0.1% cresyl violet solution for 15 min. Slides were 
then rinsed in  H2O and incubated in acetic acid for 4–8 s. Slides were then dehydrated in 100% ethanol for 1 min 
and cleared in 100% xylene prior mounting with DPX mountant. Images were collected using a nanozoomer 
digital slide scanner (Hamamatsu) and analysed in NDP.view 2 software (Hamamatsu). Motor neurons were 
then counted using a criteria of > 20 μm in cell body size in any axis, location I the ventral horn and presence of 
a nucleus and nucleolus. Counting of motor neurons was conducted blinded.
Iba1 and GFAP staining. Sections were deparrafinised and rehydrated as above and subjected to antigen 
retrieval at pH 9 using Access super RTU (Menarini) for 30 min at 125 °C with 20 psi. After antigen retrieval, 
sections were cooled and washed in PBS for 5 min. Sections were then blocked and permeabilised using 5% BSA 
(Sigma Aldrich) and 0.25% triton 100 (Thermo Scientific) for 20 min. Then incubated with the primary anti-
bodies 1 in 500 dilution in 1% BSA and 0.25% triton 100 overnight at 4 °C. Primary antibodies were anti-GFAP 
raised in chicken (abcam, ab4674) and anti-Iba1 raised in rabbit (GeneTex, GTX100042).
Primary antibodies were washed off with 6 quick PBS washes and 3 washes in PBS with agitation. The slides 
were then incubated with the secondary antibodies 1 in 1000 for 1.5 h at room temperature. Secondary antibod-
ies were alexa flour anti-rabbit 555 raised in donkey (Thermo Fisher, A27039) and Alexa fluor anti-chicken 488 
raised in donkey (Thermo Fisher, A11039). Secondary antibodies were removed with 2 quick PBS washes and 
4–8 min washes in PBS with agitation. Slides were the mounted using hard set vectashield with DAPI (Vector 
Laboratories) and cover slips were added. Fluorescent images were captured using the INCELL 2000 (GE) at a 
magnification of 60x. Images were analysed using ImageJ where the background was subtracted using a rolling 
ball and a default threshold (“Li”) was used to detect both GFAP and Iba1 staining. This threshold was then used 
as a mask to analyse the original image. This method was adapted from Healy et al.37.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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